ISSN: 2165-7092
Pancreatic Disorders & Therapy
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

The Role of EMT in Pancreatic Cancer Progression

Keywords
Pancreatic cancer; EMT; Stem cell; MicroRNA; Natural compounds
Pancreatic Cancer (PCa) is one of the most common malignancies in the United States. According to American Cancer Society surveys, it is estimated that 44,030 new PCa cases have been occurred and 37,660 patients diagnosed with PCa died in 2011 [1]. The causes of PCa development are largely unclear even though multiple studies indicated that many factors such as family history, smoking, obesity, diet, diabetes mellitus, and chronic pancreatitis are correlated with increased incidence of PCa [2]. The current treatments for PCa patients include surgery, radiation and chemotherapy. Although the treatments have been improved during past decades, the five-year survival rate is only approximately 6% [1]. One of the reasons is due to fact that about 80% of all PCa patients have locoregional spread and/or distant metastasis [1]. Therefore, understanding the molecular mechanisms underlying the metastasis of PCa is required to improve the survival in patients diagnosed with this deadly disease.
In recent years, many genes and cellular signaling pathways have been found to be involved in the invasion and metastasis in PCa. For example, our studies have demonstrated that Notch signaling pathway promotes migration and invasion through upregulation of NF-κB (Nuclear Factor-Kappa b) and its target gene such as MMP-9 (Matrix Metallopeptidase-9) and VFGF (Vascular Endothelial Growth Factor) in PCa [3]. Moreover, we found that PDGF-D (Platelet-Derived Growth Factor-D) promoted cell invasion through Notch-1 and NF- κB signaling in PCa [4]. One group led by Batra reported that MUC4 potentiates invasion and metastasis of PCa cells through stabilization of FGFR-1 (Fibroblast Growth Factor Receptor-1) [5]. Recently, it has been shown that concurrent inhibition of c-Met and VEGF signaling suppresses the tumor invasion and metastasis in pancreatic neuroendocrine tumors [6].
Recently, it has been indicated that EMT (Epithelial to Mesenchymal Transition) plays a crucial role in the invasion and metastasis of PCa. It is well known that EMT occurs normally during embryonal development, which is characterized by loss of epithelial cell-cell contacts through inhibition of E-cadherin, ZO-1, occludin, claudin-1, and claudin-7 [7]. In parallel, cells acquire mesenchymal features such as upregulation of Slug, Snail, ZEB1 (Zinc-Finger E-Box Binding Homeobox 1), ZEB2, Twist as well as Vimentin, and production of matrix proteins, leading to cell migration and invasion [7]. Multiple studies have indicated that EMT occurred in the progression of human cancers; however, it has no direct evidence to approve this concept due to the fact that EMT is transient and lacks the specific markers. In addition, the molecular mechanisms by which EMT occurs are not fully elucidated so far.
Accumulating evidence has revealed that many growth factors and cytokines as well as cellular signaling pathways could trigger EMT program such as TGFβ transforming growth factor beta, Wnt, Notch, NF-κB, EGF (Epidermal Growth Factor), HGF (Hepatocyte Growth Factor), and PDGF in PCa cells [8-11]. For example, our studies have shown that the activation of Notch signaling is mechanistically associated with EMT phenotype of PCa cells [12]. To support the role of Notch signaling pathway in EMT, we observed that over-expression of Notch-1 led to the induction of EMT phenotype through activation of mesenchymal cell markers including ZEB1 and EpCAM, suggesting that the activation of Notch-1 signaling contributes to the acquisition of EMT phenotype in PCa cells [9]. Similarly, we found that overexpression of FoxM1 caused the acquisition of EMT phenotype via up regulating mesenchymal cell markers including ZEB1, ZEB2, Snail 2 and Vimentin in PCa cells [13]. Consistent with this notion, Thiery et al. [7] found that FoxM1-Caveolin1 promoted EMT in both mouse and human PCa cells [14]. Additionally, hypoxia has been reported to induce EMT, resulting in promoting metastasis of PCa cells, demonstrating that antioxidants may be useful therapeutic agents for treatment of PCa [15]. Interestingly, Joost et al. [16] reported that inhibition of Hedgehog pathway effector transcription factor Gli1 promotes EMT in PCa cells [16]. These results suggest that further investigation is necessary to explore the mechanisms underlying EMT progression.
Since micorRNAs (miRNAs), 21-25 nucleotide RNA molecules that govern the translation and stability of mRNAs, have been found to be involved in tumor invasion and metastasis in PCa, research scientists hypothesize that miRNAs might play a critical role in regulation of EMT. Indeed, one study from Brabletz group showed that ZEB1 triggers the miR-200 family-mediated feedforward loop that promotes EMT and invasion of PCa cells [17]. Moreover, this group demonstrated that ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs including miR-203, miR-183 and miR-200 family in PCa cells [18]. Consistent with these results, the abundance of miR-200 family was correlated positively with E-cadherin expression and negatively with the expression of EMT-associated transfactor [19]. To further support the role of miR- 200 in regulating EMT, Yu et al. [20] also found a remarkably strong correlation between the levels of miR-200c and E-cadherin expression in PCa cells [20]. Recently, one study revealed that DCAMKL-1 controls EMT via a miR-200-dependent mechanism in PCa, indicating that it has a direct regulatory links between DCAMKL-1, miRNAs, and EMT in PCa [21]. More recently, miR-126 was found to regulate ADAM9 and induce E-cadherin, suggesting that miR-126/ADAM9 axis inhibits the cell invasion partly through regulation of EMT in PCa cells [22]. Taken together, miRNAs play pivotal roles in governing EMT in PCa.
Interestingly, a growing body of evidence suggests that EMT-type cells have CSCs (Cancer Stem Cells) characteristics in a variety of human malignancies including PCa. It is accepted that CSCs, which have been identified using different sets of stem cell surface markers in various types of human cancers, possess the ability to self-renew and generate the diverse cell population [23]. The cell surface markers for pancreas-specific CSCs are CD44, CD24, ESA (Epithelial Specific Antigen), and CD133 [23]. To support the link between EMT and CSCs in PCa, Shah et al. [24] found that EMT-type cells have increased expression of the stem cell markers CD24, CD44, and ESA [24]. In line with this notion, our previous studies have revealed that PCa cells with EMT phenotype have increased sphere-forming capacity and high expression of CSC surface markers such as CD44 and EpCAM [13]. To this end, targeting EMT could reduce the population of CSCs that have been implicated in tumor metastasis and drug resistance. Without a doubt, further studies are required to explore the molecular mechanisms of how EMT-type cells acquire the CSCs features.
Strikingly, EMT-type cells have been shown to contribute to drug resistance in PCa. For example, the study led by Choi showed that EMT-type cells are resistant to gemcitabine, 5-FU (5-fluorouracil) and cisplatin, while non-EMT-type cells are sensitive to these chemotherapeutic drugs [25]. Furthermore, they found that ZEB1 and other regulators of EMT could maintain drug resistance in human PCa cells [25]. Similarly, the study from our group showed that E-cadherin was down-regulated and Vimentin was up-regulated in Gemcitabine- Resistant (GR) PCa cells [26]. Consistent with this concept that EMT plays a critical role in drug resistance, generated GR PCa cells from gemcitabine sensitive PCa cells are also associated with EMT [24]. Specifically, GR cells have down-regulation of E-cadherin and upregulation of Vimentin [24]. Moreover, we found that acquisition of EMT phenotype of GR cells is correlated with over-expression of the Notch signaling pathway [12]. In parallel, another group reported that activation of Notch signaling increased chemoresistance in part due to induction of EMT in PCa cells [27]. Additionally, PCa cells resistant to chemoradiotherapy showed phenotypic and molecular changes consistent with EMT, including increased Vimentin and decreased E-cadherin. [28]. Furthermore, these resistant cells expressed high levels of stem cell markers Oct4, CD24, and CD133, indicating that chemoradiation resistance-induced EMT is associated with CSCs generation [28]. More recently, Carbone et al. [29] discovered that anti-VEGF treatment-resistant PCa cells secrete proinflammatory factors to induce EMT [29]. Altogether, EMT plays an important role in regulation of drug resistance in PCa, suggesting that targeting EMT could contribute to increased sensitivity to chemotherapy.
In summary, EMT has been found to play critical roles in the control of tumor invasion, metastasis and drug resistance in PCa. Several factors, cytokines and cellular signaling pathways such as Notch, FoxM1, and Hedgehog could trigger EMT. Moreover, miRNAs have been reported to govern the induction of EMT through regulating its target mRNAs. More importantly, specific natural compounds could partially reverse the EMT phenotype to MET, resulting in the reversal of drug resistance. Therefore, targeting EMT-type cells by non-toxic natural agents could be a novel potential therapeutic strategy for treatment of metastatic PCa.
Acknowledgements
This work was supported by funding from the NSFC (81172087), and Anhui Provincial Natural Science Foundation (1208085MH170). This work was also funded by grants from the National Cancer Institute, NIH CA154321 awarded to F.H.S.
References

Visit for more related articles at Pancreatic Disorders & Therapy

Keywords
Pancreatic cancer; EMT; Stem cell; MicroRNA; Natural compounds
Pancreatic Cancer (PCa) is one of the most common malignancies in the United States. According to American Cancer Society surveys, it is estimated that 44,030 new PCa cases have been occurred and 37,660 patients diagnosed with PCa died in 2011 [1]. The causes of PCa development are largely unclear even though multiple studies indicated that many factors such as family history, smoking, obesity, diet, diabetes mellitus, and chronic pancreatitis are correlated with increased incidence of PCa [2]. The current treatments for PCa patients include surgery, radiation and chemotherapy. Although the treatments have been improved during past decades, the five-year survival rate is only approximately 6% [1]. One of the reasons is due to fact that about 80% of all PCa patients have locoregional spread and/or distant metastasis [1]. Therefore, understanding the molecular mechanisms underlying the metastasis of PCa is required to improve the survival in patients diagnosed with this deadly disease.
In recent years, many genes and cellular signaling pathways have been found to be involved in the invasion and metastasis in PCa. For example, our studies have demonstrated that Notch signaling pathway promotes migration and invasion through upregulation of NF-κB (Nuclear Factor-Kappa b) and its target gene such as MMP-9 (Matrix Metallopeptidase-9) and VFGF (Vascular Endothelial Growth Factor) in PCa [3]. Moreover, we found that PDGF-D (Platelet-Derived Growth Factor-D) promoted cell invasion through Notch-1 and NF- κB signaling in PCa [4]. One group led by Batra reported that MUC4 potentiates invasion and metastasis of PCa cells through stabilization of FGFR-1 (Fibroblast Growth Factor Receptor-1) [5]. Recently, it has been shown that concurrent inhibition of c-Met and VEGF signaling suppresses the tumor invasion and metastasis in pancreatic neuroendocrine tumors [6].
Recently, it has been indicated that EMT (Epithelial to Mesenchymal Transition) plays a crucial role in the invasion and metastasis of PCa. It is well known that EMT occurs normally during embryonal development, which is characterized by loss of epithelial cell-cell contacts through inhibition of E-cadherin, ZO-1, occludin, claudin-1, and claudin-7 [7]. In parallel, cells acquire mesenchymal features such as upregulation of Slug, Snail, ZEB1 (Zinc-Finger E-Box Binding Homeobox 1), ZEB2, Twist as well as Vimentin, and production of matrix proteins, leading to cell migration and invasion [7]. Multiple studies have indicated that EMT occurred in the progression of human cancers; however, it has no direct evidence to approve this concept due to the fact that EMT is transient and lacks the specific markers. In addition, the molecular mechanisms by which EMT occurs are not fully elucidated so far.
Accumulating evidence has revealed that many growth factors and cytokines as well as cellular signaling pathways could trigger EMT program such as TGFβ transforming growth factor beta, Wnt, Notch, NF-κB, EGF (Epidermal Growth Factor), HGF (Hepatocyte Growth Factor), and PDGF in PCa cells [8-11]. For example, our studies have shown that the activation of Notch signaling is mechanistically associated with EMT phenotype of PCa cells [12]. To support the role of Notch signaling pathway in EMT, we observed that over-expression of Notch-1 led to the induction of EMT phenotype through activation of mesenchymal cell markers including ZEB1 and EpCAM, suggesting that the activation of Notch-1 signaling contributes to the acquisition of EMT phenotype in PCa cells [9]. Similarly, we found that overexpression of FoxM1 caused the acquisition of EMT phenotype via up regulating mesenchymal cell markers including ZEB1, ZEB2, Snail 2 and Vimentin in PCa cells [13]. Consistent with this notion, Thiery et al. [7] found that FoxM1-Caveolin1 promoted EMT in both mouse and human PCa cells [14]. Additionally, hypoxia has been reported to induce EMT, resulting in promoting metastasis of PCa cells, demonstrating that antioxidants may be useful therapeutic agents for treatment of PCa [15]. Interestingly, Joost et al. [16] reported that inhibition of Hedgehog pathway effector transcription factor Gli1 promotes EMT in PCa cells [16]. These results suggest that further investigation is necessary to explore the mechanisms underlying EMT progression.
Since micorRNAs (miRNAs), 21-25 nucleotide RNA molecules that govern the translation and stability of mRNAs, have been found to be involved in tumor invasion and metastasis in PCa, research scientists hypothesize that miRNAs might play a critical role in regulation of EMT. Indeed, one study from Brabletz group showed that ZEB1 triggers the miR-200 family-mediated feedforward loop that promotes EMT and invasion of PCa cells [17]. Moreover, this group demonstrated that ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs including miR-203, miR-183 and miR-200 family in PCa cells [18]. Consistent with these results, the abundance of miR-200 family was correlated positively with E-cadherin expression and negatively with the expression of EMT-associated transfactor [19]. To further support the role of miR- 200 in regulating EMT, Yu et al. [20] also found a remarkably strong correlation between the levels of miR-200c and E-cadherin expression in PCa cells [20]. Recently, one study revealed that DCAMKL-1 controls EMT via a miR-200-dependent mechanism in PCa, indicating that it has a direct regulatory links between DCAMKL-1, miRNAs, and EMT in PCa [21]. More recently, miR-126 was found to regulate ADAM9 and induce E-cadherin, suggesting that miR-126/ADAM9 axis inhibits the cell invasion partly through regulation of EMT in PCa cells [22]. Taken together, miRNAs play pivotal roles in governing EMT in PCa.
Interestingly, a growing body of evidence suggests that EMT-type cells have CSCs (Cancer Stem Cells) characteristics in a variety of human malignancies including PCa. It is accepted that CSCs, which have been identified using different sets of stem cell surface markers in various types of human cancers, possess the ability to self-renew and generate the diverse cell population [23]. The cell surface markers for pancreas-specific CSCs are CD44, CD24, ESA (Epithelial Specific Antigen), and CD133 [23]. To support the link between EMT and CSCs in PCa, Shah et al. [24] found that EMT-type cells have increased expression of the stem cell markers CD24, CD44, and ESA [24]. In line with this notion, our previous studies have revealed that PCa cells with EMT phenotype have increased sphere-forming capacity and high expression of CSC surface markers such as CD44 and EpCAM [13]. To this end, targeting EMT could reduce the population of CSCs that have been implicated in tumor metastasis and drug resistance. Without a doubt, further studies are required to explore the molecular mechanisms of how EMT-type cells acquire the CSCs features.
Strikingly, EMT-type cells have been shown to contribute to drug resistance in PCa. For example, the study led by Choi showed that EMT-type cells are resistant to gemcitabine, 5-FU (5-fluorouracil) and cisplatin, while non-EMT-type cells are sensitive to these chemotherapeutic drugs [25]. Furthermore, they found that ZEB1 and other regulators of EMT could maintain drug resistance in human PCa cells [25]. Similarly, the study from our group showed that E-cadherin was down-regulated and Vimentin was up-regulated in Gemcitabine- Resistant (GR) PCa cells [26]. Consistent with this concept that EMT plays a critical role in drug resistance, generated GR PCa cells from gemcitabine sensitive PCa cells are also associated with EMT [24]. Specifically, GR cells have down-regulation of E-cadherin and upregulation of Vimentin [24]. Moreover, we found that acquisition of EMT phenotype of GR cells is correlated with over-expression of the Notch signaling pathway [12]. In parallel, another group reported that activation of Notch signaling increased chemoresistance in part due to induction of EMT in PCa cells [27]. Additionally, PCa cells resistant to chemoradiotherapy showed phenotypic and molecular changes consistent with EMT, including increased Vimentin and decreased E-cadherin. [28]. Furthermore, these resistant cells expressed high levels of stem cell markers Oct4, CD24, and CD133, indicating that chemoradiation resistance-induced EMT is associated with CSCs generation [28]. More recently, Carbone et al. [29] discovered that anti-VEGF treatment-resistant PCa cells secrete proinflammatory factors to induce EMT [29]. Altogether, EMT plays an important role in regulation of drug resistance in PCa, suggesting that targeting EMT could contribute to increased sensitivity to chemotherapy.
In summary, EMT has been found to play critical roles in the control of tumor invasion, metastasis and drug resistance in PCa. Several factors, cytokines and cellular signaling pathways such as Notch, FoxM1, and Hedgehog could trigger EMT. Moreover, miRNAs have been reported to govern the induction of EMT through regulating its target mRNAs. More importantly, specific natural compounds could partially reverse the EMT phenotype to MET, resulting in the reversal of drug resistance. Therefore, targeting EMT-type cells by non-toxic natural agents could be a novel potential therapeutic strategy for treatment of metastatic PCa.
Acknowledgements
This work was supported by funding from the NSFC (81172087), and Anhui Provincial Natural Science Foundation (1208085MH170). This work was also funded by grants from the National Cancer Institute, NIH CA154321 awarded to F.H.S.
References

Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acute Pancreatitis
Disc Acute Pancreatitis Symptoms
Disc Advanced Type 1 Diabetes Treatment
Disc Advanced Type 2 Diabetes Treatment
Disc Advances of Diabetes Cure
Disc Anal Cancer Diagnosis
Disc Biliary Dyskinesia
Disc Bladder Cancer Diagnosis
Disc Blood Cancer Diagnosis
Disc Brain Cancer Diagnosis
Disc Breast Cancer Diagnosis
Disc Cancer Diagnosis
Disc Cervical Cancer Diagnosis
Disc Childhood Diabetes
Disc Chronic Pancreatitis
Disc Colon Cancer Diagnosis
Disc Complications of Hyperglycemia
Disc Complications of Hypoglycemia
Disc Constipation
Disc Diabetes Cholestrol
Disc Diabetes Lipid Metabolism
Disc Diabetes Statistics
Disc Diabetes and Alcohol
Disc Diabetes and Weight Loss
Disc Diabetes for Dummies
Disc Digestive Enzymes
Disc Endoscopy
Disc Epigastric Pain
Disc Esophageal Cancer Diagnosis
Disc GIST Sarcoma
Disc Gall Bladder
Disc Gall Bladder Symptoms
Disc Gallbladder Disease
Disc Gallstone Pancreatitis
Disc Gastric Cancer
Disc Gastrointestinal Bleeding
Disc Gastrointestinal Hormones
Disc Gastrointestinal Infections
Disc Gastrointestinal Inflammation
Disc Gastrointestinal Pathology
Disc Gastrointestinal Pharmacology
Disc Gastrointestinal Radiology
Disc Gastrointestinal Surgery
Disc Gastrointestinal Tuberculosis
Disc Hereditary Pancreatitis
Disc Inflamed Pancreas
Disc Intestinal Blockage
Disc Kidney Cancer Diagnosis
Disc Latest Research on Diabetes
Disc Leukemia Diagnosis
Disc Liver Cancer Diagnosis
Disc Lung Cancer Diagnosis
Disc Lymphoma Diagnosis
Disc Mesothelioma Diagnosis
Disc Mouth Cancer Diagnosis
Disc Obesity and Diabetes
Disc Ovarian Cancer Diagnosis
Disc Pancreas
Disc Pancreas Anatomy
Disc Pancreas Pain
Disc Pancreatectomy
Disc Pancreatic Cancer Diagnosis
Disc Pancreatic Disorder
Disc Pancreatic Duct
Disc Pancreatic Enzyme Replacement Therapy
Disc Pancreatitis
Disc Pancreatitis Symptoms
Disc Pathophysiology of Diabetes
Disc Prostate Cancer Diagnosis
Disc Proton Therapy Pancreatic Cancer
Disc Rectal Cancer Diagnosis
Disc Reverse Diabetes
Disc Salivary Glands
Disc Skin Cancer Diagnosis
Disc Stomach Bloating
Disc Stomach Cramps
Disc Stomach Disorders
Disc Stomach Ulcer
Disc Swollen Pancreas
Disc Testicular Cancer Diagnosis
Disc Thyroid Cancer Diagnosis
Disc Type 1 Diabetes
Disc Type 2 Diabetes
Disc Uterine Cancer Diagnosis
 
Recommended Journals
Disc Endocrinology Journal
Disc Diabetes Journal
Disc Cancer Diagnosis Journal
Disc Pancreas Journal
Disc Gastrointestinal Journal
  View More»
 
Recommended Conferences
Disc Hepatitis Vaccines Summit
Sep 26-28, 2016, Valencia, Spain
Disc 3rd Hepatitis and Liver Diseases Summit
Oct 17-19, 2016, Dubai, UAE
View More»
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 3763
  [From(publication date):
October-2012 - May 26, 2016]
  Breakdown by view type
  HTML page views : 34
  PDF downloads :3729
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version